Opioid Damages and Health Care Costs Recovery Act, SBC 2018, c. 35
Section 1
Definitions and interpretation
Cite as Opioid Damages and Health Care Costs Recovery Act, SBC 2018, c. 35, s. 1 · read from BC Laws on November 17, 2026
The text
(1) In this Act:
“active ingredient” means an active ingredient set out in the Schedule;
“consultant” means a person who provides advisory services
(a) to a wholesaler in relation to the distribution, sale or offering for sale of opioid products, or
(b) to a manufacturer in relation to the sale of active ingredients or opioid products;
“cost of health care benefits” means,
(a) in relation to an action under section 2 (1), the sum of
(i) the present value of the total expenditure by the government for health care benefits provided for insured persons as a result of opioid-related disease, injury or illness or the risk of opioid-related disease, injury or illness, and
(ii) the present value of the estimated total expenditure by the government for health care benefits that could reasonably be expected to be provided for those insured persons as a result of opioid-related disease, injury or illness or the risk of opioid-related disease, injury or illness, and
(b) in relation to an action under section 2.1 (1), the sum of
(i) the present value of the total expenditure by the government of Canada for health care benefits provided for insured persons as a result of opioid-related disease, injury or illness or the risk of opioid-related disease, injury or illness, and
(ii) the present value of the estimated total expenditure by the government of Canada for health care benefits that could reasonably be expected to be provided for those insured persons as a result of opioid-related disease, injury or illness or the risk of opioid-related disease, injury or illness;
“disease, injury or illness” includes problematic substance use, addiction and general deterioration of health;
“health care benefits” means,
(a) in relation to an action under section 2 (1),
(i) benefits as defined under the Hospital Insurance Act,
(ii) benefits as defined under the Laboratory Services Act,
(iii) benefits as defined under the Medicare Protection Act,
(iv) benefits as defined under the Pharmaceutical Services Act,
(v) payments made by the government under the Continuing Care Act, and
(vi) other expenditures by the government, made directly or through one or more agents or other intermediate bodies, for programs, services, benefits or similar matters associated with disease, injury or illness, and
(b) in relation to an action under section 2.1 (1), expenditures by the government of Canada for programs, services, benefits or similar matters associated with disease, injury or illness;
“insured person” means
(a) a person, including a deceased person, for whom health care benefits have been provided, or
(b) a person for whom health care benefits could reasonably be expected to be provided;
“joint venture” means an association of 2 or more persons, if
(a) the relationship among the persons does not constitute a corporation, partnership or trust, and
(b) the persons each have an undivided interest in assets of the association;
“manufacture” includes, for an opioid product, the production, assembly and packaging of the opioid product;
“manufacturer” means a person who manufactures or has manufactured an active ingredient or opioid product and a person who, in the past or currently,
(a) causes, directly or indirectly, through arrangements with contractors, subcontractors, licensees, franchisees or others, the manufacture of an active ingredient or opioid product,
(b) for any fiscal year of the person, derives at least 10% of revenues, determined on a consolidated basis in accordance with generally accepted accounting principles in Canada, from the manufacture or promotion of active ingredients or opioid products by that person or by other persons,
(c) engages in or causes, directly or indirectly, other persons to engage in promoting an active ingredient or opioid product, or
(d) is a trade association primarily engaged in
(i) advancing the interests of manufacturers,
(ii) promoting an active ingredient or opioid product, or
(iii) causing, directly or indirectly, other persons to engage in promoting an active ingredient or opioid product;
“opioid product” means any product that contains
(a) a drug or active ingredient set out in the Schedule, or
(b) a drug or active ingredient prescribed by regulation;
“opioid-related disease, injury or illness” means disease, injury or illness caused or contributed to by an individual's use or exposure to an opioid product, whether the opioid product is
(a) in the form in which it was manufactured,
(b) combined with another drug or substance, or
(c) used, or in the case of exposure is present, in a form or manner other than
(i) as prescribed or advised by a practitioner, or
(ii) as recommended by the manufacturer of that opioid product;
“opioid-related wrong” means
(a) a tort that is committed in British Columbia by a manufacturer, wholesaler or consultant and that causes or contributes to opioid-related disease, injury or illness, or
(b) in an action under section 2 (1) or 2.1 (1), a breach, by a manufacturer, wholesaler or consultant, of a common law, equitable or statutory duty or obligation owed to persons in British Columbia who have used or been exposed to or might use or be exposed to an opioid product;
“person” includes a trust, joint venture or trade association;
“practitioner” means a person who
(a) is authorized under the Health Professions and Occupations Act or the Veterinarians Act to prescribe or advise on the therapeutic value, contents and hazards of a drug within the meaning of the Pharmacy Operations and Drug Scheduling Act, and
(b) is not prohibited from prescribing a drug that is an opioid product;
“promote” or “promotion” includes, for an opioid product,
(a) the marketing of the opioid product, whether direct or indirect,
(b) the distribution or sale of the opioid product, and
(c) any research with respect to the opioid product;
“type of opioid product” means an opioid product in the form of a pill, a capsule, an oral liquid, a powder, an injectable, a topical or a combination of any of these;
“use or exposure”, in relation to an opioid product, means ingestion, inhalation, injection, application or assimilation of the opioid product, whether intentional or otherwise;
“wholesaler” means a person who distributes, sells or offers for sale opioid products
(a) to pharmacies, distributors or other persons for resale, or
(b) to hospitals, facilities or care centres for patient use.
(2) The definition of "manufacturer" in subsection (1) does not include
(a) an individual,
(b) a wholesaler or retailer of opioid products who is not related to
(i) a person who manufactures an opioid product, or
(ii) a person described in paragraph (a) of the definition of "manufacturer", or
(c) a person who
(i) is a manufacturer only because paragraph (b) or (c) of the definition of "manufacturer" applies to the person, and
(ii) is not related to
(A) a person who manufactures an opioid product, or
(B) a person described in paragraphs (a) or (d) of the definition of "manufacturer".
(3) For the purposes of subsection (2) of this section, a person is related to another person if, directly or indirectly, the person is
(a) an affiliate, as defined in section 1 of the Business Corporations Act, of the other person, or
(b) an affiliate of the other person or an affiliate of an affiliate of the other person.
(4) For the purposes of subsection (3) (b), a person is deemed to be an affiliate of another person if the person
(a) is a corporation and the other person, or a group of persons not dealing with each other at arm's length of which the other person is a member, owns a beneficial interest in shares of the corporation
(i) carrying at least 50% of the votes for the election of directors of the corporation, and the votes carried by the shares are sufficient, if exercised, to elect a director of the corporation, or
(ii) having a fair market value, including a premium for control if applicable, of at least 50% of the fair market value of all the issued and outstanding shares of the corporation, or
(b) is a partnership, trust or joint venture, and the other person, or a group of persons not dealing with each other at arm's length of which the other person is a member, has an ownership interest in the assets of that person that entitles the other person or group of persons to receive at least 50% of the profits or at least 50% of the assets on the dissolution, winding up or termination of the partnership, trust or joint venture.
(5) For the purposes of subsection (3) (b), a person is deemed to be an affiliate of another person if the other person, or a group of persons not dealing with each other at arm's length of which the other person is a member, has any direct or indirect influence that, if exercised, would result in control in fact of that person, except if the other person or group of persons deals at arm's length with that person and derives influence solely as a lender.
(6) For the purposes of determining the market share of a manufacturer for a type of opioid product sold in British Columbia, the court must calculate the manufacturer's market share for the type of opioid product by the following formula: mms = mm × 100% MM where mms is the manufacturer's market share for the type of opioid product from the date of the earliest opioid-related wrong committed by that manufacturer to the date of trial; mm is the quantity of the type of opioid product manufactured by the manufacturer that is distributed, sold or offered for sale within British Columbia from the date of the earliest opioid-related wrong committed by that manufacturer to the date of trial; MM is the quantity of the type of opioid product manufactured by all manufacturers that is purchased or dispensed within British Columbia for the purpose of providing health care benefits from the date of the earliest opioid-related wrong committed by the manufacturer to the date of trial.
(7) For the purposes of determining the market share of a wholesaler for a type of opioid product sold in British Columbia, the court must calculate the wholesaler's market share for the type of opioid product by the following formula: wms = wm × 100% WW where wms is the wholesaler's market share for the type of opioid product from the date of the earliest opioid-related wrong committed by that wholesaler to the date of trial; wm is the quantity of the type of opioid product that is distributed, sold or offered for sale by the wholesaler within British Columbia from the date of the earliest opioid-related wrong committed by that wholesaler to the date of trial; WW is the quantity of the type of opioid product that is distributed, sold or offered for sale within British Columbia for the purpose of providing health care benefits from the date of the earliest opioid-related wrong committed by the wholesaler to the date of trial.
Read the Opioid Damages and Health Care Costs Recovery Act on BC Laws ↗